The Company sponsors a noncontributory defined benefit pension plan, under which participation and benefit accruals ceased as of December 31, 1996 and it provides retiree medical benefits, consisting of the opportunity to purchase coverage at subsidized rates under the Company's group medical plan.

Information related to the defined benefit pension plan maintained by Renasant Bank (“Pension Benefits”) and to the post-retirement health and life plan (“Other Benefits”) as of the dates presented is as follows:



	Pension Benefits						Other Benefits
	Three Months Ended						Three Months Ended
	June 30,						June 30,
	2020		2019		2020		2019
Service cost	$	—	$	—	$	1	$	1
Interest cost	250		315		2		8
Expected return on plan assets	(413)		(362)		—		—

Recognized actuarial loss (gain)	96		135		(27)		3

Net periodic (return) benefit cost	$	(67)	$	88	$	(24)	$	12



	Pension Benefits						Other Benefits
	Six Months Ended						Six Months Ended
	June 30,						June 30,
	2020		2019		2020		2019
Service cost	$	—	$	—	$	3	$	3
Interest cost	492		588		7		16
Expected return on plan assets	(826)		(725)		—		—

Recognized actuarial loss (gain)	175		221		(45)		(11)

Net periodic (return) benefit cost	$	(159)	$	84	$	(35)	$	8

The Company maintains a long-term equity compensation plan that provides for the grant of stock options and the award of restricted stock. There were no stock options granted, nor compensation expense associated with options recorded, during the six months ended June 30, 2020 or 2019.

The following table summarizes information about options outstanding, exercised and forfeited as of and for the six months ended June 30, 2020:


	Shares	Weighted Average Exercise Price
Options outstanding at beginning of period	29,250	$	15.86
Granted	—	—
Exercised	—	—
Forfeited	—	—
Options outstanding at end of period	29,250	$	15.86

The Company also awards performance-based restricted stock to executives and other officers and employees and time-based restricted stock to non-employee directors, executives, and other officers and employees.

The following table summarizes the changes in restricted stock as of and for the six months ended June 30, 2020:


	Performance-Based Restricted Stock	Weighted Average Grant-Date Fair Value		Time-Based Restricted Stock	Weighted Average Grant-Date Fair Value
Nonvested at beginning of period	115,725	$	34.00	500,932	$	36.34
Awarded	81,423	35.42		235,293	34.35
Vested	—	—		(124,094)	38.37
Cancelled	(2,233)	33.70		(30,645)	37.16
Nonvested at end of period	194,915	$	34.60	581,486	$	35.06

During the six months ended June 30, 2020, the Company reissued 138,644 shares from treasury in connection with the exercise of stock options and awards of restricted stock. The Company recorded total stock-based compensation expense of $2,998 and $2,082 for the three months ended June 30, 2020 and 2019, respectively and $5,748 and $4,719 for the six months ended June 30, 2020 and 2019, respectively.